Funder: Breakthrough T1D
Due Dates: Rolling (LOIs accepted year-round by invitation or in response to RFAs)
Funding Amounts: Typically up to $3,000,000 total over 3 years; company matching funds required; no indirect costs allowed.
Summary: Supports for-profit organizations developing therapeutics or devices for type 1 diabetes that align with Breakthrough T1D’s research priorities, with a focus on commercial potential and regulatory advancement.
Key Information: Contact Breakthrough T1D staff before submitting an LOI; matching funds from company required.